Juan Manuel O’Connor, MD, Institute Alexander Fleming, Buenos Aires, Argentina, shares his highlights from the ESMO World Congress on Gastrointestinal Cancer 2021, which included data from the Phase III open-label KEYNOTE-177 trial (NCT02563002), which assessed pembrolizumab in patients with microsatellite-instability–high advanced colorectal cancer. Additional highlights include results from the Phase III BEACON trial (NCT02928224), which investigated encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.